rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EBS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution (NYSE:EBS)

      Emergent BioSolutions faces margin pressure, lowered FY26 guidance, and weak profitability despite cost cuts. Learn more about EBS stock here.

      Nov 6Seeking AlphaEBS
      Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs on ...
      Nov 5Yahoo FinanceEBS
      Emergent BioSolutions Inc. Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceEBS
      Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
      Nov 3Yahoo FinanceEBS
      Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript
      Nov 3The Globe and MailEBS
      Emergent Biosolutions: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceEBS
      Emergent Biosolutions Q3 Earnings Call Highlights
      Nov 2Yahoo FinanceEBS
      Earnings call transcript: Emergent BioSolutions misses Q3 2026 estimates, shares fall
      Nov 2Investing.comEBS
      Emergent BioSolutions Q3 2026 Earnings Call Transcript
      Nov 2BenzingaEBS
      Emergent Biosolutions earnings missed by $0.23, revenue fell short of estimates
      Nov 2Investing.comEBS
      Emergent Biosolutions Reports Third Quarter 2026 Financial Results
      Nov 2Yahoo FinanceEBS
      Emergent BioSolutions Announces CFO Transition Amid Transformation

      Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

      Oct 17The Globe and MailEBS
      Why is Emergent Biosolutions stock sliding today?
      Oct 16Investing.comEBS
      Emergent BioSolutions stock falls as CFO plans retirement
      Oct 16Investing.comEBS
      Emergent BioSolutions CFO to retire, treasurer named interim
      Oct 16Investing.comEBS
      Emergent BioSolutions CFO Richard Lindahl to Retire at Year-End
      Oct 16Yahoo FinanceEBS
      Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
      Oct 16Yahoo FinanceEBS
      Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
      Oct 15Yahoo FinanceEBS
      Emergent BioSolutions director DeGolyer sells $126k in shares
      Oct 7Investing.comEBS
      Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?

      Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

      Oct 6Yahoo FinanceEBS
      Why is Emergent Biosolutions stock surging today?
      Oct 5Investing.comEBS
      Emergent BioSolutions SVP Paul Williams sells $19,590 in stock
      Oct 5Investing.comEBS
      Emergent Stock: The MCM Engine Runs, But Naloxone Is Breaking Down (NYSE:EBS)

      Emergent BioSolutions (EBS) outlook: MCM strength vs. NARCAN impairment and naloxone decline. Read here for a detailed investment analysis.

      Sep 15Seeking AlphaEBS
      Emergent BioSolutions at H.C. Wainwright conference: debt falls
      Sep 14Investing.comEBS
      Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

      Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans

      Sep 7Yahoo FinanceVALNEBS
      Emergent BioSolutions - Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS)

      Emergent BioSolutions (EBS) downgraded to Hold as Narcan sales slip, competition rises and debt persists; review risks, cash flow signals and act now.

      Sep 6Seeking AlphaEBS
      Emergent BioSolutions repurchases $75 million in senior notes
      Sep 3Investing.comEBS
      Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028

      Emergent BioSolutions (EBS) said Thursday that it has completed the repurchase of $75 million aggreg

      Sep 3Yahoo FinanceEBS
      Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

      Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Dir

      Sep 3Yahoo FinanceEBS
      Emergent BioSolutions receives $24M anthrax vaccine contract
      Sep 1Investing.comEBS
      Emergent BioSolutions Wins $24 Million BARDA Contract for Anthrax Vaccine
      Sep 1Yahoo FinanceEBS
      Emergent BioSolutions wins Canada contract for overdose spray
      Aug 31Investing.comEBS

      This is the newest page. Registered accounts read further back.